Tofacitinib does not affect platelet function or coagulation in patients with ulcerative colitis

Background

Tofacitinib is a Janus kinase inhibitor used to treat inflammatory diseases, including rheumatoid arthritis and ulcerative colitis (UC). Previous studies have reported an increased risk of thromboembolic events in patients with rheumatoid arthritis treated with tofacitinib. Therefore, evaluating whether these effects are also present in other inflammatory diseases such as UC is important.

Methods